Abstract. We examined whether phenoxazine derivatives such as 2-amino-4,4·-dihydro-4·,7-dimethyl-3H-phenoxazine-3-one (Phx-1) and 2-aminophenoxazine-3-one (Phx-3) may have anticancer effects on the human gastric cancer cell lines, MKN45, MKN74, MKN7 and KATO III in vitro. Phx-1 inhibited the growth of these cancer cells in a dose-and timedependent manner. The IC 50 was approximately 65, 25, 100 and 70 μM for MKN45, MKN74, MKN7 and KATO III respectively, after 72 h. Phx-3 exerted stronger antiproliferative effects against these cancer cells (IC 50 : approximately 5, 1, 10 and 10 μM for MKN45, MKN74, MKN7 and KATO III, respectively, after 72 h) than Phx-1. Phx-1 and Phx-3 increased the population of TUNEL-positive cells in MKN45 and KATO III time-dependently from 24 to 72 h, suggesting that Phx-1 and Phx-3 have apoptotic activity against these gastric cancer cells. The activity of effector caspase-3 significantly increased in MKN45 treated with Phx-3 for 24 h, but did not altered in the cells treated with Phx-1 for 24 h. When z-VAD-fmk, a pan-caspase inhibitor, was co-treated for 24 h, Phx-3-stimulated caspase-3 activity in MKN45 was reversed to the levels of normal activity, while the antiproliferative and apoptotic effects of Phx-3 against the cells were maintained. The activity of caspase-3 was not activated in KATO III by 24 h exposure for Phx-1 or Phx-3. In conclusion, both phenoxazines prevent the growth of the human gastric cancer cell lines, MKN45 and KATO III in vitro, and cause the apoptosis of these cell lines via a caspase-independent pathway. Although the intracellular action mechanisms of Phx-1 and Phx-3 are still unclear, these phenoxazines may be useful for the treatment of gastric cancer in the future.
Introduction
Gastric cancer, a malignant tumor arising from the region between esophagogastric junction and the pylorus, is common worldwide, and is difficult to cure by chemotherapy alone (1, 2) . Anticancer drugs such as 5-fluorouracil and cisplatin used for its treatment could induce severe adverse effects (3, 4) . We therefore need anticancer drugs, inducing apoptosis of cancer cells at low doses, to minimize adverse effects (5) (6) (7) .
Since the discovery of Actinomycin D, which includes phenoxazine in its chemical structure and exerts strong anticancer activity (8, 9) , phenoxazine compounds have been studied as possible anticancer drugs. However, the chemically synthesized phenoxazines showed little anticancer activity (10, 11) , probably because of lower solubility in water. Recently, it has been reported that phenoxazine derivatives, 2-amino-4,4·-dihydro-4·,7-dimethyl-3H-phenoxazine-3-one (Phx-1) and 2-aminophenoxazine-3-one (Phx-3), which were produced by the reaction of o-aminophenol and its derivative with bovine hemoglobin (12, 13) and are relatively soluble in water, exert anticancer effects on a variety of carcinoma cells (14) (15) (16) (17) (18) both in vitro and in vivo. In particular, these phenoxazines were found to show little adverse effects on mice (14, 19, 20) . However, the anticancer effects of Phx-1 and Phx-3 on the human gastric cancer cell lines, extremely refractory to chemotherapeutic reagents (1,2), have not been examined. In addition, though it was shown that Phx-1 and Phx-3 cause apoptosis of some carcinoma cell lines (14) (15) (16) (17) (18) , the detailed pathways for apoptosis caused by Phx-1 and Phx-3 have not been sufficiently investigated in these cases.
In the present study, we investigated the anticancer effects of Phx-1 and Phx-3 on the human gastric cancer cell lines, MKN45 and KATO III, focusing on caspase-dependent or caspase-independent apoptotic cell death in gastric cancer cell lines.
Materials and methods
Phenoxazine derivatives. Phenoxazines, 2-amino-4,4·-dihydro-4·,7-dimethyl-3H-phenoxazine-3-one (Phx-1) and 2-aminophenoxazine-3-one (Phx-3) were prepared according to the methods described by Tomoda et al (12) and Shimizu et al (13) . The chemical structure of these compounds is illustrated in Fig. 1 . Phx-1 and Phx-3 were dissolved in a mixture of dimethylsulfoxide (DMSO) and ethyl alcohol (EtOH) (3:1) to make 20 mM solutions, which were added to the culture medium to reach final concentrations of 1.25-100 μM.
Cell lines and culture condition. The human gastric cancer cell lines, MKN45, MKN74, MKN7, KATO III, were obtained from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). MKN45, MKN74 and MKN7 and KATO III were poorly-differentiated adenocarcinoma, moderatelydifferentiated tubular adenocarcinoma, well-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. These cells were cultured in Eagle's minimum essential medium · (MEM·) (Kohjin Bio, Saitama, Japan) supplemented with 80 mg/l kanamycin sulfate (Wako Pure Chemicals, Tokyo, Japan) and 10% heat inactivated fetal bovine serum (FBS) (Sigma, St. Louis, MO, USA) in a humidified incubator containing 5% CO 2 /95% air at 37˚C.
Cell viability assay. The viability of cells was assessed fluorometrically using the CellTiter-Blue™ Cell Viability Assay (Promega, Madison, WI, USA). Adherent cells such as MKN45 (1x10 5 cells/ml), MKN74 (1x10 5 cells/ml) and MKN7 (5x10 4 cells/ml) were pre-cultured in 48-well flat-bottomed microtiter plates for 24 h, and then treated with fresh culture medium containing various concentrations of Phx-1 (0-100 μM) or Phx-3 (0-20 μM). Non-adherent cells such as KATO III (1x10 5 cells/ml) were treated with various concentrations of Phx-1 (0-100 μM) or Phx-3 (0-40 μM) in 6-well flatbottomed microtiter plates. After 24, 48 and 72 h of treatment, MKN45, MKN74 and MKN7 were treated with fresh culture medium, and then the CellTiter-Blue TM reagent (Resazurin, 7-hydroxy-3H-phenoxazin-3-one 10-oxide) was added in each well, while KATO III was collected by centrifugation, resuspended in fresh culture medium, and dispensed in 48-well flat-bottomed microtiter plate. The incubation was continued for 1 h, resorufin (7-hydroxy-3H-phenoxazin-3-one), reduced form of resazurin, was analyzed using a multi- (8 μl) and ultrapure water (32.25 μl), which were incubated at 37˚C for 1 h. Then, the cells were twice rinsed with 1 ml of the rinse buffer, and stained with 500 μl of the propidium iodide/RNase A solution, then incubated at room temperature for 30 min in the dark. These samples were analyzed with a flow cytometer (Partec PAS, Partec). FITC and PI staining were monitored using an FITC signal detector (FL1, 520 nm) and phycoerythrin emission signal detector (FL3, 590-650 nm), respectively.
Measurement of caspase-3 in MKN45 and KATO III.
The activity of caspase-3 was measured fluorometrically using the DEVD-AFC, LEHD-AFC and IETD-AFC (MBL), respectively. MKN45 and KATO III (1x10 5 cells/ml) were treated with the indicated concentrations of Phx-1 or Phx-3, or vehicle for 6-72 h in a 75 cm 2 cell culture flask. The cells were collected, washed once with PBS (pH 7.4) and treated with 200 μl of the cell lysis buffer (MBL), which were incubated on ice for 10 min. These lysates were diluted by adding 300 μl of the dilution buffer (MBL), and then 50 μl of the 2X reaction buffer (MBL) and 5 μl of DEVD-AFC, LEHD-AFC or IETD-AFC were added to 50 μl aliquots, which were incubated at 37˚C for 1 h in the dark. These samples were analyzed using a multi-detection microplate reader (Powerscan HT, Dainippon Pharmaceutical) at a wavelength of 400 nm excitation/505 nm emission. The activity of caspase-3/7 was triplicated, corrected by protein contents, and expressed as the relative ratio of the activity in cells treated with Phx-1 or Phx-3 to that in control cells treated with vehicle at each time-point.
Examination of the effects of a caspase inhibitor on caspase-3 and apoptosis in MKN45 and KATO III.
In the present study, a pan-caspase inhibitor, N-benzyloxy-carbonyl-Val-Ala-Aspfluoromethylketone (z-VAD-fmk) (MBL) was used. This chemical was dissolved in DMSO to make 20 mM solution, and then this solution was added in culture medium to reach a final concentration of 50 μM during experiments. MKN45 or KATO III was divided into four groups as follows: i) control cells treated with vehicle, ii) cells treated with the indicated concentrations of Phx-1 or Phx-3, iii) cells treated with z-VADfmk, and iv) cells treated with the indicated concentrations of Phx-1 or Phx-3 and z-VAD-fmk. The third and fourth group cells were pre-treated with z-VAD-fmk for 1 h, while the first and second group cells were pre-treated with the same quantity of DMSO for the same period. Then, the treatment of cells with Phx-1, Phx-3 or vehicle, and z-VAD-fmk or DMSO was performed for 24 h. The activity of caspase-3 and the viability of cells were examined, and the detection of apoptosis was performed as described above.
Cell cycle analysis. The analysis of cell cycle was performed flow cytometrically using the CyStain DNA 2 step (Partec, Münster, Germany). MKN45 and KATO III (1x10 5 cells/ml) were treated with the indicated concentrations of Phx-1 or Phx-3, or vehicle (DMSO/EtOH) for 24, 48 and 72 h in 25 cm 2 cell culture flask. Then, the cells were collected, once washed with phosphate-buffered saline (PBS, pH 7.4) and treated with 1 ml of the nuclei extraction buffer, which were incubated at room temperature for 10 min. The extracted nuclei were stained with 5 ml of the 4'-6-diamidino-2-phenylindole (DAPI) staining regent and incubated at room temperature for 10 min in the dark. These samples were analyzed with a flow cytometer using the cell cycle analysis program, MultiCycle AV (Phoenix Flow System, San Diego, CA, USA).
Statistical analysis. Experimental data are presented as means ± SE. Unpaired Student's t-test was performed to examine the differences between each experimental group cells. A p-value <0.5 was considered to indicate a statistically significant difference.
Results
Antiproliferative effects of Phx-1 and Phx-3 on the human gastric cancer cell lines, MKN45, MKN74, MKN7 and KATO III. Antiproliferative effects of various concentrations of Phx-1 and Phx-3 on the growth of 4 characteristic human gastric cancer cell lines, MKN45, MKN74, MKN7 and KATO III were studied, 24, 48 and 72 h after treatment of these phenoxazines. Both Phx-1 and Phx-3 exhibited antiproliferative effects on MKN45, MKN74 and MKN7, timeand dose-dependently ( Fig. 2A-C) . The IC 50 of Phx-1 was 65, 25 and 100 μM for MKN45, MKN74 and MKN7 cells, respectively, after 72 h. Phx-3 exerted stronger antiproliferative effects on these cancer cells (IC 50 : ~5, 1 and 10 μM for MKN45, MKN74 and MKN7, respectively, after 72 h).
Phx-1 moderately inhibited the growth of KATO III, timeand dose-dependently (Fig. 2D, left column) . The IC 50 of Phx-1 was ~70 μM for KATO III, after 72 h. Phx-3 exerted stronger antiproliferative effects on KATO III (IC 50 : ~10 μM after 72 h; Fig. 2D, right column) . KATO III are non-adherent cells that originate from signet ring cell carcinoma, and MKN45, MKN74 and MKN7 are adherent to a culture plate. Furthermore, MKN45 and KATO III are undifferentiated cancer cells with higher malignancy. Thus, we investigated the apoptotic mechanism of MKN45 and KATO III caused by Phx-1 and Phx-3 in the following experiments.
Effects of Phx-1 and Phx-3 on apoptosis/necrosis in human gastric cancer cell lines, MKN45 and KATO III.
We studied whether the prevention of cell growth of MKN45 and KATO III caused by Phx-1 and Phx-3 was associated with induction of cell death such as apoptosis and necrosis. As shown in the left columns of Fig. 3A and B, the population of cells negative on both TUNEL and PI (viable cells, plots in the bottom left quadrant) was mostly observed in the control cells treated with vehicle in both MKN45 and KATO III during 24-72 h. When MKN45 were treated with 100 μM Phx-1 or 7.5 μM Phx-3 for 24-72 h (Fig. 3A, middle and after 24, 48 and 72 h for Phx-1, respectively; 9.7, 23.0 and 24.2% after 24, 48 and 72h for Phx-3, respectively. top right quadrant in the figure), respectively, increased in a timedependent manner. Similar effects were observed in KATO III treated with 100 μM Phx-1 or 10 μM Phx-3 (Fig. 3B) . These results indicate that Phx-1 and Phx-3 are capable of inducing mixed type of cell death -apoptosis and necrosis in human gastric cancer cell lines, MKN45 and KATO III.
Changes in capase-3 activity in human gastric cancer cell lines, MKN45 and KATO III treated with Phx-1 or Phx-3.
The activity of caspase-3 was examined as a function of time (h) in MKN45 and KATO III treated with Phx-1 or Phx-3 for 0-72 h, in order to elucidate the involvement of apoptotic signaling pathway in the apoptosis/necrosis of these cells (Fig. 4) . Caspase-3 was not activated in MKN45 during 72 h exposure for 100 μM Phx-1 (Fig. 4A, left column) , while it was activated as much as 3.2 times by 24 h exposure for 7.5 μM Phx-3 (Fig. 4A, right column) . Caspase-3 was slightly activated after 24 h, and markedly activated after 48 h (3.9 times of the control) in KATO III treated with 100 μM Phx-1 (Fig. 4B, left column) , but it was slightly activated after 24 h, and moderately activated after 48 h in the cells treated with 20 μM Phx-3 (2.2-2.5 times of the control) (Fig. 4B, right  column) . Consequently, caspase-3 activity was significantly activated at 24 h only in MKN45 treated with Phx-3.
Involvement of caspase-independent pathway in the apoptogenesis in gastric cancer cell lines, MKN45 and KATO III.
Caspase-3 has been considered to be involved in the apoptogenesis in cancer cells treated with anticancer drugs (21, 22) . On the other hand, Park et al (23) recently reported that caspase-independent pathway may be involved in the apoptogenesis in gastric cancer cells. We found that caspase-3 activity in MKN45 was significantly augmented by Phx-3 at 24 h (Fig. 4, right column) . Therefore, we studied whether the apoptogenic effects of Phx-3 in MKN45 at 24 h may be dependent on the elevation of activity of caspase-3 or not, by using the pan-caspase inhibitor, z-VAD-fmk. Phx-3-caused growth inhibition and apoptosis induction in MKN45 may be dependent on the activation of caspase-3, it is possible that z-VAD-fmk cancels the inhibition of the growth, apoptosis induction of the cells and the augmented activity of caspase-3 caused by Phx-3.
As shown in Fig. 5A , caspase-3 activity was activated in MKN45 treated with 7.5 μM Phx-3 alone at 24 h, and it was completely cancelled by treatment with 50 μM z-VAD-fmk in MKN45. However, Phx-3-caused inhibition of the viability of MKN45 was not reversed to normal levels by co-treatment with z-VAD-fmk (Fig. 5B) .
When MKN45 was treated with z-VAD-fmk alone, the population of apoptosis/necrosis cells was not changed compared with control cells (Fig. 5C ). The population of apoptosis/ necrosis cells was significantly increased in MKN45 cells treated with Phx-3, however, it was not reversed to the normal levels, when MKN45 was treated with both Phx-3 and z-VAD-fmk (Fig. 5C ). These results (Fig. 5) suggest that the Phx-3-induced inhibition of cell viability and apoptosis/ necrosis in MKN45 were not associated with the activation of caspase-3.
Effects of Phx-1 and Phx-3 on cell cycle arrest in MKN45 and KATO III. We studied the effects of Phx-1 and Phx-3 on cell cycle arrest in MKN45 and KATO III. As shown in Fig. 6A, Phx-1 caused G 0 /G 1 phase arrest in MKN45, while Phx-3 induced arrest at the S-phase. However, neither Phx-1 nor Phx-3 caused cell cycle arrest in KATO III (Fig. 6B) .
Discussion
We investigated whether Phx-1 and Phx-3, which are relatively water-soluble compared with other chemically synthesizedphenoxazines, may prevent cellular growth and cause induction of caspase-dependent or independent apoptosis in gastric cancer cells. We used the human gastric cancer cell lines MKN45, MKN74, MKN7 cells and KATO III. The growth of these cells was significantly inhibited by Phx-1 or Phx-3 in a dose-and time-dependent manner (Fig. 2) . The IC 50 of Phx-1 and Phx-3 in these cells ranged from 1 to 100 μM, and these values were comparable to IC 50 of these phenoxazines in various cancer cells (14) (15) (16) (17) (18) (19) , and to those of 5-fluorouracil in human gastric cancer cells (3) , suggesting that Phx-1 and Phx-3 may be cytotoxic to gastric cancer cells. MKN45 is relatively sensitive to chemothera-peutic agents such as 5-fluorouracil (3) and troglitazone (24) , while KATO III has been demonstrated to be extremely refractory to these agents. In this context, the behavior of Phx-1 and Phx-3 was different, because these phenoxazines caused growth inhibition of each of the gastric cancer cell lines, MKN45, MKN74, MKN7 and KATO III. It has been recognized that drugs causing apoptosis in cancer cells exert less adverse effects, because apoptotic cells are engulfed by phagocytes whereas the membrane of necrotic cells is disrupted, and inflammation and release of toxic substances occur. Thus, the apoptogenic drugs may be beneficial for treating cancers. We showed that Phx-1 or Phx-3-induced growth inhibition of MKN45 and KATO III, which are more malignant than MKN74 and MKN7, was associated with apoptosis/necrosis (Fig. 3) , suggesting that these pheno-xazines may be beneficial agents to treat gastric cancer.
The activation of caspase family proteases, including caspase-3 is considered to be involved in cellular apoptosis (21, 22) . However, according to recent reports (25) (26) (27) , a caspase-independent pathway associated with apoptosis inducing factor (AIF) and Bcl-2/19 kDa interacting protein-3 (BNIP3) is operating in induction of apoptosis. Park et al (23) indicated that allicin, a major component of garlic, causes apoptosis in gastric carcinoma cells through caspaseindependent cell death pathway, accompanying the release of AIF from mitochondria instead of the activation of caspase-3. We demonstrated that caspase-3 was not activated at 24 h in MKN45 treated with Phx-1 and in KATO III treated with Phx-1 and Phx-3 (Fig. 4) , while it was much activated at 24 h in MKN45 treated with Phx-3 (Fig. 4A) . These results suggest that activation of caspase-3 was not involved in the apoptogenesis in MKN45 with Phx-1 and in KATO III with Phx-1 or Phx-3. Furthermore, with regard to MKN-45 treated with Phx-3, apoptosis and growth inhibition of MKN45 caused by Phx-3 was not reversed to normal levels by z-VAD-fmk, a pan-caspase inhibitor ( Fig. 5B and C) , in spite of the cancellation of activation of caspase-3 (Fig. 5A) . These results strongly suggest that induction of apoptosis in human gastric cancer cell lines, MKN45 and KATO III is not caused by the activation of caspase-3, but may be related with some caspase-independent pathways including AIF and BNIP3 (25) (26) (27) .
The prevention of cancer cells by anticancer drugs is shown to be linked to the cell cycle arrest (28, 29) . The results in Fig. 6A and B show that the progression of cell cycle was arrested at G 0 /G 1 phase in MKN45 treated with Phx-1, and at G 0 /G 1 and S-phase in the cells with Phx-3 (Fig. 6A ). This result is consistent with the reports that Phx-1 and Phx-3 prevented the cell cycle progression at various phases, i.e., arrest at G 0 /G 1 in human malignant melanoma G-361 cells with Phx-3 (16) , and arrest at S and G 2 /M in human epidermoid carcinoma cell line KB with Phx-1 (30) and human leukemia cell line HAL-01 with Phx-1 (14) .
With regard to human malignant melanoma (16) and pancreatic cancer cells lines (18) , antiproliferative effects of Phx-3 were stronger than those of Phx-1, which agrees with the present results on human gastric cancer cell lines (Fig. 2) . Such differences in action mode between Phx-1 and Phx-3 may be the variation in chemical structure between these phenoxazines, i.e., the presence or absence of the methyl group in the tricyclic chromophore (Fig. 1) , though details of the mechanism are still obscure.
Gastric cancers are very common tumors in adults (1,2), but are often refractory to anticancer drugs. Thus, it is urgent to develop drugs exerting anticancer effects but with low adverse reaction. Present results suggest that Phx-1 and Phx-3 hold promise as agents to treat gastric cancer in the future.
